Fortress Biotech CFO Robyn Hunter resigns; David Jin appointed CFO effective Aug 16

Fortress Biotech, Inc.

CFO Robyn Hunter steps down after 11 years to pursue external opportunities; transition support through year-end.
David Jin, current VP of Corporate Development and interim CEO/CFO of subsidiary Avenue Therapeutics, named CFO.
Jin previously held roles at Barings, Sorrento Therapeutics, and FBR & Co, involved in over $3.5B in transactions.
Jin will continue as Head of Corporate Development and is eligible for standard executive compensation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Jin

Chief Financial Officer

FBIO · Fortress Biotech, Inc.

Effective: 2022-08-16
Filed: July 22, 2022, 7:59 PM ET

effective August 16, 2022, David Jin, 32, who has served as the Company’s Vice President of Corporate Development and the Interim Principal Executive Officer and Chief Operating Officer of the Company’s subsidiary Avenue Therapeutics, Inc. (“Avenue”), was appointed Chief Financial Officer.

Departed

Robyn Hunter

Chief Financial Officer

FBIO · Fortress Biotech, Inc.

Effective: 2022-08-16
Successor: David Jin
Filed: July 22, 2022, 7:59 PM ET

On July 21, 2022, Robyn Hunter, the Chief Financial Officer of Fortress Biotech, Inc. (the “Company”), provided notice to the Company of her resignation. Ms. Hunter’s resignation will be effective August 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David Jin was appointed as Chief Financial Officer at Fortress Biotech, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

effective August 16, 2022, David Jin, 32, who has served as the Company’s Vice President of Corporate Development and the Interim Principal Executive Officer and Chief Operating Officer of the Company’s subsidiary Avenue Therapeutics, Inc. (“Avenue”), was appointed Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Robyn Hunter resigned as Chief Financial Officer at Fortress Biotech, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On July 21, 2022, Robyn Hunter, the Chief Financial Officer of Fortress Biotech, Inc. (the “Company”), provided notice to the Company of her resignation. Ms. Hunter’s resignation will be effective August 16, 2022.

View on SEC.gov

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-010916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.